Oligonucleotide– tag –
-
China’s AsymBio Secures $184M to Dramatically Expand Biologics CDMO Capacity, Bolstering ADC Production
PharmaSource China Overview AsymBio, a Chinese biologics CDMO, secured approximately $184 million (1.2397 billion Yuan) in financing to substantially expand its manufacturing capacity, R&D capabilities, GMP manufacturing lines, and h... -
LNP Design Innovations Enable Extrahepatic Nucleic Acid Delivery: Paving Way for Mucosal Administration Routes
MDPI Switzerland Overview Recent breakthroughs in lipid nanoparticle (LNP) design, driven by altered formulation composition and chemical modification of ionizable lipids, are enabling organ-selective nucleic acid delivery beyond the liv... -
Bioengineering Strategies Overcome Liver Tropism to Improve Cardiac Targeting of LNPs for Heart Disease Therapy
Arteriosclerosis, Thrombosis, and Vascular Biology - American Heart Association Journals USA Overview Despite promise in cardiovascular disease treatment, nanomedicines face challenges of insufficient cardiac targeting and poor retention... -
VERVE-101 Achieves 53-69% LDL-C Reduction in Lipid Disorder Trials, Accelerating LNP-Based Gene Editing Therapeutics
PMC (Part of MDPI) Switzerland Overview VERVE-101, an in vivo base editing therapy targeting PCSK9 via mRNA-LNP delivery, has progressed to clinical trials (NCT05398029) for lipid disorders, showing significant LDL-C reductions of 53% to... -
Bispecific Antibody-Conjugated Lipid Nanoparticles Achieve Cell-Specific mRNA Delivery, Overcoming Liver Tropism
ACS Publications USA Overview Researchers have developed a bispecific antibody-conjugated lipid nanoparticle (TbsAb-LNP) platform designed for precise, cell-specific mRNA delivery, effectively circumventing the inherent liver tropism of ... -
Ribo’s Divesiran (SLN124) Significantly Reduces Phlebotomy Frequency and Improves Patient QoL in Polycythemia Vera Phase IIa Trial
MPN Research Foundation Global Overview Divesiran (SLN124) from Ribo is an siRNA therapy designed to increase hepcidin levels, aiming to control erythrocyte overproduction in polycythemia vera (PV). Clinical trial results showed that pat... -
Heart-Specific LNP Delivery for Myocardial Infarction Remains a Challenge: Conventional LNPs Accumulate in Liver, while Novel Lipid Engineering Targets Lungs and Spleen
American Heart Association Journals USA Overview Lipid nanoparticles (LNPs) are clinically validated non-viral vectors for delivering therapeutics like small molecules, mRNA, and siRNA; however, achieving heart-specific drug delivery for... -
Molecular Glue Development Accelerates: Gluetacs and Degron Advance Key Programs in Targeted Protein Degradation
GlobeNewswire Global Overview The field of molecular glues, a powerful targeted protein degradation (TPD) modality, is rapidly expanding with two significant clinical advancements: Gluetacs Therapeutics has initiated a Phase II trial for... -
Non-Endocytic Membrane-Translocating Delivery Strategies Bypass Endosomal Barriers for Gene, mRNA, and Protein Therapies
Drug Target Review UK Overview A new review evaluates non-endocytic membrane-translocating delivery strategies designed to circumvent insufficient endosomal escape efficiency, a major hurdle for many next-generation therapeutics. These e... -
bioRxiv Preprint: Novel ‘Post-Loading’ Strategy for RNA into Empty Lipid Nanoparticles Solves Cold Chain Challenges
bioRxiv USA Overview A bioRxiv preprint introduces a novel 'post-loading' strategy for RNA into lipid nanoparticle (LNP) carriers. This method allows empty LNPs to be manufactured and stored separately, with RNA loaded just prior to admi...
